Abstract: Objective To explore and analyze the effectiveness of Tongxinluo capsules in treating elderly patients with coronary heart disease and angina pectoris. Methods From May 2021 to May 2023, 100 elderly patients with coronary heart disease and angina pectoris at the People's Hospital of Inner Mongolia Autonomous Region were selected and divided into an observation group (treated with telmisartan combined with Tongxinluo capsules) based on different treatment methods; The control group (treated with telmisartan alone), with 50 cases each. Comparative analysis of cardiac function indicators, quality of life, incidence of angina pectoris, thioredoxin interaction protein (TXNIP), and chemokine CX3C ligand 1(CX3CL1) indicators in patients undergoing 1-month intervention. Results After treatment, the left ventricular ejection fraction in the observation group was higher than that in the control group, while the left ventricular end systolic diameter, left ventricular end diastolic diameter, and left atrial diameter were lower (P<0.05); The social, environmental, physical, and psychological factors in the observation group were higher than those in the control group (P<0.05); The frequency of angina attacks in the observation group was lower than that in the control group, and the duration of angina was shorter, with a statistically significant difference (P<0.05); The levels of CX3CL1 and TXNIP indicators in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion The combination of Tongxinluo Capsule intervention for elderly patients with coronary heart disease and angina pectoris can improve the level of cardiac function indicators and the quality of life of patients, shorten the onset time of angina pectoris, and reduce the frequency of episodes.

Key words: elderly patients with coronary heart disease and angina pectoris, Tongxinluo, telmisartan, efficacy evaluation, quality of life